Fuscan: a robust DNA fusion caller for targeted sequencing data in cancer diagnostics.
MOTIVATION: Gene fusions resulting from genomic structural variation in somatic cells have been increasingly identified as central events driving oncogenesis. We benchmarked Fuscan against established SV callers, achieving an area under the curve (AUC) of 0.992 and demonstrating its robustness in challenging clinical scenarios, including low-tumor-content tissues and liquid biopsies.
MOTIVATION: Gene fusions resulting from genomic structural variation in somatic cells have been increasingly identified as central events driving oncogenesis. We benchmarked Fuscan against established SV callers, achieving an area under the curve (AUC) of 0.992 and demonstrating its robustness in challenging clinical scenarios, including low-tumor-content tissues and liquid biopsies.
What the study was
- Study design
- Not specified
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Bioinformatics advances
Why it surfaced
Relevant Precision oncology and genomic medicine study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.